Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2906 Kcal01
Potent PDZ domain peptide inhibitor that rescues CFTR activity
More description
DCC2905 Kca2 Positive Modulator 2q
Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels
More description
DCC2904 Kca-1490
Dual PDE3/4 inhibitor
More description
DCC2903 Kca075
Highly specific transglutaminase 2 (TG2) inhibitor
More description
DCC2902 Kc-11404
LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase
More description
DCC2901 Kb-r7785
Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in
More description
DCC2900 Kbp-088
Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss
More description
DCC2899 Kb-nb165-09
Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication
More description
DCC2898 Kbjk557
Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells
More description
DCC2897 Kbh-a42
Novel histone deacetylase inhibitor
More description
DCC2896 Kb130015
Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages
More description
DCC2895 Kasugamycin
Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis
More description
DCC2894 Kar425
Novel antimalarial agent, providing protection to malaria-infected mice
More description
DCC2893 Kalb001
Novel mGlu4 ligand
More description
DCC2892 Kaempulchraol Q
Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression
More description
DCC2891 Kaempulchraol P
Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression
More description
DCC2890 K-8012
Novel inhibitor of the interaction of the N-terminally truncated RXR
More description
DCC2889 K-8008
Novel inhibitor of the interaction of the N-terminally truncated RXR
More description
DCC2888 K4610422
Novel norditerpenoid inhibitor of testosterone-5α-reductase
More description
DCC2887 K-14585
Novel antagonist for proteinase-activated receptor 2 (PAR2)
More description
DCC2886 K103 Hydrochloride
Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor
More description
DCC2885 K00518
Novel dual CLK1 and CLK3 inhibitor
More description
DCC2884 K00135
Novel potent and selective inhibitor of PIM kinases
More description
DCC2883 Jzp-430
Potent, highly selective, and irreversible ABHD6 Inhibitor
More description
DCC2882 jzad-iv-22
Inhibitor of all three monoamine transporters
More description
DCC2881 Jz-5029
Novel irreversible β-Glucocerebrosidase modulator
More description
DCC2880 Jz-4109
Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells
More description
DCC2879 Jy-xhe-053
Selective modulator of GABAA receptors containing the α5 subunit
More description
DCC2878 Jyl-79
Potent vanilloid receptor (VR1) agonist
More description
DCC2877 Jyl-273
Potent TRPV1 agonist
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X